ONC212 in Oncology

ONC212 is an agonist of the orphan GPCR tumor suppressor GPR132, as well as an agonist of ClpP. Similar to the downstream effects of ONC201 and ONC206, it activates the integrated stress response and induces TRAIL-mediated apoptosis in tumor cells. ONC212 has broad-spectrum activity across both solid tumors and hematological malignancies, including pancreatic cancer and leukemias prioritized as target clinical indications that exhibit high GPR132 and/or ClpP expression.

For more information on ONC212, please refer to our Publications and to the ‘Our Science’ section of our website.

Development of ONC212

Oncoceutics has entered an alliance agreement with the MD Anderson Cancer Center for Phase I and Phase II trials of ONC212 in patients with acute leukemias.

The United States Patent and Trademark Office (USPTO) has issued a patent providing the company with composition of matter protection for ONC212.